- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Stephen Marmaras: Value and Co-Payment Assistance Programs
Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses value and patient co-payment assistance programs.
Transcript:
Are patient-assistance programs on the whole good or bad?
Well, we know that many of our community members rely on them to receive their therapy, so they’re very important. I think what is also important with patient-assistance programs is understanding that sometimes they can be abused. Our fear is that when they are abused, or when they’re used by individuals that may not actually need them, so to speak, it could compromise patient-assistance programs in general for the folks that are most vulnerable and need them.
I would point to a white paper that our organization did in collaboration with the University of Michigan [Center for Value-Based Insurance Design]. It looks at precision patient-assistance programs [and] how we can identify those vulnerable patients most at risk from a clinical standpoint and from a financial standpoint and making sure that co-pay assistance programs are available specifically to those individuals so that we can get people on the right treatment quickly.
I think it’s a balance. I think we need to be more responsible about applying co-pay assistance programs to individuals so that we can guarantee that they’ll be around for a longer period of time.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
